tag:www.gov.uk,2005:/search/news-and-communicationsNews and communications2025-07-18T12:46:31+01:00HM Governmenttag:www.gov.uk,2005:/government/news/mhra-approves-adrenaline-nasal-spray-the-first-needle-free-emergency-treatment-for-anaphylaxis-in-the-uk2025-07-18T12:46:31+01:00MHRA approves adrenaline nasal spray - the first needle-free emergency treatment for anaphylaxis in the UKThe Medicines and Healthcare products Regulatory Agency (MHRA) has today, 18 July 2025, approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as …tag:www.gov.uk,2005:/government/news/mhra-approves-elinzanetant-to-treat-moderate-to-severe-vasomotor-symptoms-hot-flushes-caused-by-menopause2025-07-08T00:00:00+01:00MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 8 July, become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flus…tag:www.gov.uk,2005:/government/news/mhra-publishes-final-business-plan-for-2023-2026-corporate-plan2025-06-25T11:10:09+01:00MHRA publishes final Business Plan for 2023-2026 Corporate Plan The new Business Plan sets out priorities for 2025–26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives …tag:www.gov.uk,2005:/government/news/mhra-approves-uks-first-anti-pd-1-monoclonal-antibody-for-treatment-of-aggressive-form-of-lung-cancer2025-06-20T16:06:30+01:00MHRA approves UK’s first anti-PD-1 monoclonal antibody for treatment of aggressive form of lung cancerAs with all products, we will keep its safety under close reviewtag:www.gov.uk,2005:/government/news/chikungunya-vaccine-ixchiq-temporarily-paused-in-people-aged-65-and-over-as-precautionary-measure2025-06-09T14:04:20+01:00Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measureThis is a precautionary measure while the MHRA conducts the safety review.
tag:www.gov.uk,2005:/government/news/women-on-skinny-jabs-must-use-effective-contraception-mhra-urges-in-latest-guidance2025-06-05T00:01:03+01:00Women on “skinny jabs” must use effective contraception, MHRA urges in latest guidance Anyone who suspects that they’ve had an adverse reaction to their weight loss or diabetes medicine or suspects it is not a genuine product, should report it to the MHRA. tag:www.gov.uk,2005:/government/news/mhra-approves-aumolertinib-to-treat-non-small-cell-lung-cancer2025-06-03T00:00:00+01:00MHRA approves aumolertinib to treat non-small cell lung cancerAs with all products, we will keep its safety under close reviewtag:www.gov.uk,2005:/government/news/mhra-approves-polihexanide-to-treat-acanthamoeba-keratitis2025-05-23T00:00:00+01:00MHRA approves polihexanide to treat acanthamoeba keratitisAs with any medicine, the MHRA will keep the safety and effectiveness of polihexanide under close review. tag:www.gov.uk,2005:/government/news/mhra-approves-vaccine-to-protect-against-pneumococcal-infections-such-as-pneumonia-and-meningitis2025-05-15T17:11:51+01:00MHRA approves vaccine to protect against pneumococcal infections such as pneumonia and meningitisAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/mhra-approves-first-uk-treatment-for-congenital-thrombotic-thrombocytopenic-purpura-cttp2025-05-12T17:41:15+01:00MHRA approves first UK treatment for congenital thrombotic thrombocytopenic purpura (cTTP) As with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/mhra-approves-teprotumumab-as-the-first-uk-treatment-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted2025-05-07T00:00:00+01:00MHRA approves teprotumumab as the first UK treatment for adults with moderate to severe Thyroid Eye Disease (TED)As with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/vimkunya-vaccine-approved-to-prevent-disease-caused-by-the-chikungunya-virus-in-people-12-years-of-age-and-older2025-05-01T16:51:31+01:00Vimkunya vaccine approved to prevent disease caused by the chikungunya virus in people 12 years of age and older The Medicines and Healthcare products Regulatory Agency (MHRA) has today (1 May 2025) approved a vaccine (Vimkunya) used to prevent disease caused by the chikungunya virus in people 12 years of age and older. tag:www.gov.uk,2005:/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes2025-04-30T15:17:40+01:00MHRA authorises cancer treatment variation with an administration time of 3–5 minutesAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/acoramidis-approved-to-treat-wild-type-or-variant-transthyretin-amyloidosis-in-adults-with-cardiomyopathy2025-04-25T11:54:57+01:00Acoramidis approved to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathyAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/obecabtagene-autoleucel-conditionally-approved-to-treat-adults-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia2025-04-25T00:00:00+01:00Obecabtagene autoleucel conditionally approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/mhra-approves-first-uk-treatment-for-friedreichs-ataxia-omaveloxolone2025-04-23T16:26:45+01:00MHRA approves first UK treatment for Friedreich’s ataxia, omaveloxoloneAs with all products, we will keep its safety under close review.tag:www.gov.uk,2005:/government/news/marstacimab-approved-to-treat-patients-aged-12-years-and-above-weighing-at-least-35-kg-with-haemophilia-a-or-b2025-04-22T11:09:20+01:00Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with haemophilia A or BAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/professor-claire-stewart-appointed-to-the-commission-on-human-medicines-as-three-members-reappointed2025-04-17T14:12:39+01:00Professor Claire Stewart appointed to the Commission on Human Medicines as three members reappointedThe appointment will involve a time commitment of 22 days per year. Remuneration for the role will be at a rate of £325 per attendance and preparation for meetings.
tag:www.gov.uk,2005:/government/news/trastuzumab-deruxtecan-approved-to-treat-adults-with-her2-positive-cancer-that-has-spread-or-cannot-be-removed-by-surgery2025-04-09T00:00:00+01:00Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that has spread or cannot be removed by surgery As with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/eplontersen-approved-to-treat-adults-with-rare-inherited-nerve-disease-or-polyneuropathy2025-04-04T11:34:24+01:00Eplontersen approved to treat adults with rare inherited nerve disease or polyneuropathyThe Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive …